Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Pediatrix Medical Group, Inc. (MD) SEC Filings & Earnings Calls

EquiReason read 12 Pediatrix Medical Group, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — Pediatrix reported Q2 2026 revenue of $487.8M (+4% YoY), net income of $39.8M (+1.5% YoY), and Adjusted EPS of $0.63 (+18.9% YoY), with operating margin declining 110bps to 11.7%..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

MDPediatrix Medical Group, Inc.Follow MD — free
Medical Care Facilities · Healthcare
—
Price chart with a free account
Market cap
2.4B
P/E TTM
14.0
Dividend yield
—
52-week
—
Next earnings
29 Oct, in 5 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

4 Aug 202610-QPediatrix reported Q2 2026 revenue of $487.8M (+4% YoY), net income of $39.8M (+1.5% YoY), and Adjusted EPS of $0.63 (+18.9% YoY), with operating margin declining 110bps to 11.7%.earningsopen

Figures in the filing · each found in the filing text

Net revenue · Q2-2026$488M+4% y/y
Net income · Q2-2026$40M+2% y/y
Adjusted EBITDA · Q2-2026$76M+4% y/y
Adjusted EPS · Q2-2026$0.63+19% y/y
Operating cash flow · H1-2026$-3M
Days Sales Outstanding · Q2-202642.5-8% y/y
Stock repurchases · H1-2026$64M

Risks flagged

Medicaid reform reduces reimbursement

“The Congressional Budget Office has estimated that the One Big Beautiful Bill Act will cut federal spending on Medicaid and Children’s Health Insurance Program benefits by $900 billion, due in part to eliminating millions of people from the programs by 2034.” · word for word

Medicare fee schedule cut

“In July 2026, CMS released the 2027 Medicare Physician Fee Schedule, which proposes to reduce the conversion factor by 1.19% for 2027.” · word for word

Surprise billing legislation uncertainty

“In May 2026, CMS finalized the most comprehensive revisions to the IDR process since its implementation. These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient’s insurer.” · word for word

Operating cash flow negative

“During the six months ended June 30, 2026, our net cash used in operating activities from continuing operations was $3.2 million, compared to cash provided of $22.0 million for the same period in 2025.” · word for word
Read the original on SEC EDGAR ↗
4 Aug 20268-K · 2.02Net Revenue $488M (+4% y/y); Net Income $40M (+1% y/y); Adjusted EBITDA $76M (+4% y/y)earningsopen

Figures in the filing · each found in the filing text

Net Revenue · Q2-2026$488M+4% y/y
Net Income · Q2-2026$40M+1% y/y
Adjusted EBITDA · Q2-2026$76M+4% y/y
Adjusted EPS · Q2-2026$0.63+19% y/y
Cash and Cash Equivalents · Q2-2026$289M
Diluted EPS · Q2-2026$0.49+7% y/y
Same-Unit Revenue Growth · Q2-20261.9%

Risks flagged

Patient volume declining 2.1% same-unit, indicating potential demand weakness.

“Same-unit patient volume decreased 2.1%.”

Transformational and restructuring expenses increased to $8.5M from $3.8M.

“Transformational and restructuring related expenses $8.5M.”
Read the original on SEC EDGAR ↗
24 Jul 20268-K · 5.02, 7.01Departure of EVP/General Counsel/CAO and appointment of new EVP/General Counsel/Secretary; separation agreement with advisory role through Oct 31, 2026.open

Risks flagged

Loss of experienced executive; transition risk in legal and administrative functions.

“Departure of EVP, General Counsel, Chief Administrative Officer and Secretary.”
Read the original on SEC EDGAR ↗
15 Jul 20268-K · 2.02, 7.01Adjusted EBITDA guidance $280M; Guidance: Adjusted EBITDA $280M-$300Mearningsopen

Figures in the filing · each found in the filing text

Adjusted EBITDA guidance · FY2026$280M

Guidance

Adjusted EBITDA $280M-$300M

Guidance reaffirmed with stable payor mix and revenue trends.

Risks flagged

Potential payor mix shifts and reimbursement pressures in healthcare sector could impact future results.

“Company confirms payor mix stable to date, but industry reports indicate shifting utilization and reimbursement trends.”
Read the original on SEC EDGAR ↗
7 May 20268-K · 5.02, 5.07Reported the departure of a director or principal officer (CEO/CFO change); submitted matters to a vote of security holdersopen

Risks flagged

Potential shareholder dilution from increased equity plan shares.

“increased the number of shares of the Company’s common stock available for issuance under the Plan by 8,000,000 shares.”
Read the original on SEC EDGAR ↗
5 May 202610-QNet revenue $476M (+4% y/y); Net income $30M (+43% y/y); Adjusted EBITDA $58M (+18% y/y)open

Figures in the filing · each found in the filing text

Net revenue · Q1-2026$476M+4% y/y
Net income · Q1-2026$30M+43% y/y
Adjusted EBITDA · Q1-2026$58M+18% y/y
Adjusted EPS · Q1-2026$0.44+33% y/y
Diluted EPS · Q1-2026$0.36+50% y/y
Operating margin · Q1-20268.7%
Days sales outstanding · Q1-2026$42.50-11% y/y
Operating cash flow · Q1-2026$-130M+12% y/y
Share repurchases · Q1-2026$22M

Risks flagged

Medicaid reimbursement cuts

“The Congressional Budget Office has estimated that the One Big Beautiful Bill Act will cut federal spending on Medicaid and Children’s Health Insurance Program benefits by $1 trillion, due in part to eliminating at least 10.5 million people from the programs by 2034.” · word for word

Surprise billing legislation impact

“These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient’s insurer, and therefore could have a material adverse effect on our business.” · word for word

Debt maturity concentration

“The Amended Credit Agreement matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of our subsidiaries and affiliated professional contractors.” · word for word
Read the original on SEC EDGAR ↗
5 May 20268-K · 2.02Net revenue $476M (+4% y/y); Net income $30M (+43% y/y); Adjusted EBITDA $58M (+18% y/y)earningsopen

Figures in the filing · each found in the filing text

Net revenue · Q1-2026$476M+4% y/y
Net income · Q1-2026$30M+43% y/y
Adjusted EBITDA · Q1-2026$58M+18% y/y
Adjusted EPS · Q1-2026$0.44+33% y/y
Diluted earnings per share · Q1-2026$0.36+50% y/y
Cash and cash equivalents · Q1-2026$206M
Net accounts receivable · Q1-2026$225M

Risks flagged

Patient volume declining (hospital-based -1.5%, office-based -3.3%) may pressure future revenue if not offset by reimbursement gains.

“Hospital-based patient services (1.5)%; Office-based patient services (3.3)%” · word for word

Seasonal cash flow use; cash balance declined significantly from year-end.

“Cash and cash equivalents of $205.8 million at March 31, 2026, compared to $375.2 million at December 31, 2025” · word for word
Read the original on SEC EDGAR ↗
27 Mar 2026DEF 14AProxy statement disclosing executive compensation structure, pay-for-performance alignment, and shareholder advisory votes.open

Figures in the filing · each found in the filing text

Adjusted Income from Operations · FY2025$231M+26% y/y
Adjusted EBITDA · FY2025$276M+23% y/y
Net Income (Loss) · FY2025$165M
Total Shareholder Return (1-year) · FY2025$87.16+63% y/y
Peer Group Total Shareholder Return · FY2025$77.88-1% y/y

Risks flagged

Reimbursement Pressure

“We continue to operate in a dynamic healthcare environment characterized by reimbursement pressures and labor market challenges” · word for word

Labor Market Challenges

“We continue to operate in a dynamic healthcare environment characterized by reimbursement pressures and labor market challenges” · word for word

Payor Mix Shift Risk

“Payor mix shifts, which represents a shift in the patient population from private healthcare insurance programs (i.e., commercial programs) to government-sponsored healthcare programs (i.e., Medicaid), are extremely difficult to forecast over both short- and long-term periods.” · word for word
Read the original on SEC EDGAR ↗
19 Feb 202610-KTotal indebtedness $597M; Days sales outstanding 42.8; Share repurchase authorization remaining $166Mopen

Figures in the filing · each found in the filing text

Total indebtedness · FY2025$597M
Days sales outstanding · FY2025$42.80
Share repurchase authorization remaining · FY2025$166M

Risks flagged

Medicaid reimbursement cut risk

“The Congressional Budget Office has estimated that the One Big Beautiful Bill Act will cut federal spending on Medicaid and Children’s Health Insurance Program benefits by $1 trillion, due in part to eliminating at least 10.5 million people from the programs by 2034.” · word for word

Physician shortage and labor cost risk

“The U.S. is currently experiencing and is expected to continue to experience a nationwide healthcare professional shortage.” · word for word

Interest rate risk on variable debt

“If interest rates continue to increase, any variable rate debt will create higher debt service requirements” · word for word

Geographic concentration risk

“During 2025 and 2024, approximately 64% and 67%, respectively, of our net revenue was generated by operations in our five largest states.” · word for word
Read the original on SEC EDGAR ↗
19 Feb 20268-K · 2.02Net revenue $494M (-2% y/y); Adjusted EBITDA $66M (-4% y/y); Adjusted EPS $0.50 (-2% y/y); Guidance: Revised upward expectationsearningsopen

Figures in the filing · each found in the filing text

Net revenue · Q4-2025$494M-2% y/y
Adjusted EBITDA · Q4-2025$66M-4% y/y
Adjusted EPS · Q4-2025$0.50-2% y/y
Same-unit net revenue growth · Q4-20254.0%

Guidance

Revised upward expectations

CEO stated Q4 results were in line with revised upward expectations; guidance raised.

Risks flagged

Volume decline in hospital-based and office-based services

“Hospital-based patient services volume decreased 3.3% year-over-year; office-based decreased 2.3%”
Read the original on SEC EDGAR ↗
3 Nov 202510-QQ3 2025 earnings: net income $71.7M vs $19.4M YoY, operating margin 13.8% vs 6.6%, Adjusted EBITDA $87.3M vs $60.2Mearningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$493M-4% y/y
Net income · Q3-2025$72M+269% y/y
Adjusted EBITDA · Q3-2025$87M+45% y/y
Adjusted EPS · Q3-2025$0.67+52% y/y
Operating cash flow · 9M-2025$160M+94% y/y
Days Sales Outstanding · 2025-09-30$43.10-17% y/y
Cash and cash equivalents · 2025-09-30$340M
Stock repurchases · 9M-2025$23M

Risks flagged

Exposure to government reimbursement changes

“Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors.” · word for word

Surprise billing legislation impact

“These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient's insurer, and therefore could have a material adverse effect on our business.” · word for word
Read the original on SEC EDGAR ↗
3 Nov 20258-K · 2.02Net revenue $493M; Net income $72M; Adjusted EBITDA $87M; Guidance: Full year 2025 Adjusted EBITDA likely range between $270 million and $290 millionearningsopen

Figures in the filing · each found in the filing text

Net revenue · Q3-2025$493M
Net income · Q3-2025$72M
Adjusted EBITDA · Q3-2025$87M
Adjusted EPS · Q3-2025$0.67
Same-unit net revenue growth · Q3-20258.0%
Same-unit revenue from net reimbursement-related factors · Q3-20257.6%
Same-unit revenue attributable to patient service volumes · Q3-20250.4%
NICU days growth · neonatology · Q3-20252.2%
Practice salaries and benefits expense · Q3-2025$332M
General and administrative expenses · Q3-2025$61M

Guidance

Full year 2025 Adjusted EBITDA likely range between $270 million and $290 million

Raised full year 2025 Adjusted EBITDA outlook range to $270M-$290M; Q3 results exceeded expectations.

Risks flagged

Healthcare environment uncertainty; potential regulatory changes.

“know that they come at a time of change and uncertainty in the healthcare environment.” · word for word
Read the original on SEC EDGAR ↗

Pediatrix Medical Group, Inc. — questions

What did Pediatrix Medical Group, Inc. file recently?
12 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — Pediatrix reported Q2 2026 revenue of $487.8M (+4% YoY), net income of $39.8M (+1.5% YoY), and Adjusted EPS of $0.63 (+18.9% YoY), with operating margin declining 110bps to 11.7%.

Every figure on this page comes from Pediatrix Medical Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.